key: cord-0889151-oll7cw6h
authors: Tsai, Her Hsin
title: COVID ‐19 and the gastroenterologist
date: 2020-05-31
journal: GastroHep
DOI: 10.1002/ygh2.401
sha: 51678579179185c61f5d66b64b11afccff937858
doc_id: 889151
cord_uid: oll7cw6h

nan

longing to the beta coronavirus genus. The virus enters cells via the angiotensin converting enzyme 2 (ACE2) receptor. ACE2 is highly expressed in gastrointestinal mucosal cells from the oesophagus to the colon. Early reports of post-mortem on patients who had showed virus affecting oesophageal tissue. 2 The virus could thus infect GI mucosal cells and survive and shed into the lumen. SARS-CoV-2 has been detected in faecal samples of 48% of patients who had diarrhoeal symptoms. Even patients without GI symptoms may shed the virus in the stool. Thus, the virus spread while patients were pre-symptomatic or asymptomatic. 3 More worryingly, the viral shedding might last for more than a month. 4 Unsurprisingly, many patients exhibit GI symptoms. The most common symptom is loss of appetite which is usual for pyrexial illness anyway as well as nausea and vomiting. Diarrhoea is variously reported to be present in up to 48% of hospitalised patients but the largest study now published of 7736 patients with Covid-19 diarrhoea was found in only 3.8%. 1 It is hard to explain the differences in reporting, but we have to assume that this symptom is not common and/or transient. There appears to be similar prevalence of diarrhoea in both with mild or severe disease. There are other confounding factors in particular the use of drugs which may cause diarrhoea in these patients, particularly antibiotics and anti-viral agents. Raised transaminases occur in 21% of infected individuals in this study and this could also be due to drugs used rather than the infection itself. 1 In another study, 29% of hospitalised patients were found to have liver injury, and 17% had evidence of pancreatic injury, as manifested by elevated pancreatic laboratory studies. 5 The second area of concern to the gastroenterologist is its effect on endoscopic procedures. The virus appears to be shed in the faeces for up to a month even after the patient becomes symptom free. This may be the case for an unknown number of asymptomatic patients The third area of concern and perhaps least addressed is the effect of the diversion of healthcare resources to the fight against COVID-19. Other services are put on hold. This includes important mortality affecting areas like cancer diagnosis and screening.

Mortality from GI cancers, in common with most cancers, is greatly affected by how early a stage it is detected. There is a worryingly number of patients who have mild GI symptoms whose diagnostic procedures may be greatly delayed by the pandemic. 6 On top of all this, lack of face-to-face clinic consultations during the lockdown may cause patients with chronic GI diseases like inflammatory bowel diseases to suffer in silence while their management remain sub-optimal.

Sound information, good science and responsible journal reporting must be upheld. In this issue of GastroHep we present two papers of considerable interest to general gastroenterologist. The first is a network meta-analysis of various treatments for decompensated liver disease in the prevention of paracentesis-induced circulatory dysfunction (PICD). They demonstrated that midodrine for 3 days is more economical and superior (or at least non-inferior) to albumin in the prevention of PICD in cirrhosis patients undergoing large volume paracentesis. 7 In another study, Minghao Li et al investigated the possible role of bisphosphonates and risk of oesophageal cancer. 8 They found after an exhaustive meta-analysis that bisphosphonates is not associated with the development of oesophageal cancer.

Editor-in-Chief GastroHep, Hull York Medical School, York, UK Email: hhtsai@yahoo.co.uk

Clinical characteristics of coronavirus disease 2019 in China

Digestive system is a potential route of COVID-19: an analysis of single-cell co-expression pattern of key proteins in viral entry process

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis

Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission

Pancreatic injury patterns in patients with COVID-19 pneumonia

COVID-19: impact on cancer workforce and delivery of care

Prevention of paracentesisinduced circulatory dysfunction-a systematic review and network meta-analysis

Bisphosphonates and risk of esophageal cancer: a metaanalysis